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Fracture healing is critically dependent upon an adequate vascular supply. The normal rate
for fracture delayed or non-union is estimated to be between 10 and 15%, and annual
fracture numbers are approximately 15 million cases per year. However, when there is
decreased vascular perfusion to the fracture, incidence of impaired healing rises dramati-
cally to 46%. Reduction in the blood supply to the fracture can be the result of traumatic
injuries that physically disrupt the vasculature and damage supportive soft tissue, the result
of anatomical location (i.e., distal tibia), or attributed to physiological conditions such as age,
diabetes, or smoking.The role of the vasculature during repair is multifaceted and changes
during the course of healing. In this article, we review recent insights into the role of
the vasculature during fracture repair. Taken together these data highlight the need for an
updated model for endochondral repair to facilitate improved therapeutic approaches to
promote bone healing.
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INTRODUCTION
Bones are highly vascularized tissues with a diverse and central
role in normal physiology; normal functions include, regulating
systemic homeostasis, enabling bone turnover, and providing a
niche for hematopoiesis. As such, it is necessary for bone regen-
eration to reestablish both the embedded osseous vasculature and
the bone marrow cavity in order to restore full functionality to
the tissue. Delay or compromise to the angiogenic process dur-
ing fracture repair has a significant effect on the progression of
proper bone healing. Ischemia at the fracture site dramatically
reduces the rate of fracture repair and is a major risk factor for
non-healing fractures, which are clinically termed “non-union” (1,
2). With an estimated 15 million fractures a year, and a delayed- or
non-union rate of close to 50% when fracture occurs in conjunc-
tion with severe vascular injury, treatment of recalcitrant fractures
represents a significant burden on the healthcare system (3, 4).
Fracture non-union is a clinical diagnosis made when a patient
has clinical symptoms that include pain, instability, and poor radi-
ographic bone healing at a time point after which healing should
be expected. Classically, three major types of non-unions have
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been described – hypertrophic, atrophic, and oligotrophic – and
are diagnosed based on the radiological evidence of bone forma-
tion. Atrophic non-unions are classically associated with a poor
biological response, including an insufficient blood supply (5),
and a major challenge in treating these cases is the restoration
of the vasculature or stimulation of new blood vessel formation.
In contrast, hypertrophic non-unions are associated with an ade-
quate biological response in the presence of excessive instability at
the fracture site, and in some cases can be successfully treated by
improved stabilization of the fracture. Oligotrophic non-unions
are not hypertrophic, but characteristically are vascular with no
callus formation due to a severely displaced fracture. The treat-
ment of non-unions frequently results in long-term patient dis-
ability, loss of wages, and can require multiple surgeries to achieve
union.
Bone grafting is one technology used to stimulate bone regen-
eration in cases of fracture non-union, or for a number of other
clinical indications that require bone formation be augmented
(i.e., spinal fusions, post-traumatic gap defects, tumor resections,
craniofacial reconstruction, and complex joint replacements) (6).
Autograft bone is the gold standard treatment in these cases and
generally produces good clinical outcomes. The most common
form for autografts is morselized cancellous bone from the iliac
crest, which effectively remodels and includes angiogenic factors
from the bone marrow in order to promote regeneration of a vas-
cularized bone. Alternatively, structural vascular autografts can be
utilized for repair. Recently procedures have been developed to
include the vascularized pedicle in the transplant, which offers a
great potential to improve outcomes, but the procedure is techni-
cally very challenging and often requires additional surgical sub-
specialties become involved. Regardless of the form factor of these
grafts, the clinical utility of autograft bone is significantly limited
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by the availability of tissue for transplantation and resultant donor
site morbidity.
Devitalized bone allografts have been developed to address
some of the clinical shortcomings of autografts. Unfortunately,
failure rates associated with allograft procedures are estimated
between 16 and 35% (7). The underlying cause for autograft fail-
ure is typically associated with their limited ability to remodel:
poor cellular and vascular invasion into the graft, along with poor
osseointegration between the graft and host tissues, results in loss
of mechanical strength and graft displacement.
The necessity of the bone regenerate to revascularize for
proper function is the end-result of a cascade of carefully coor-
dinated events that require the vasculature. This review provides
an overview of how the vasculature contributes throughout the
process of fracture healing to create a hematoma, deliver cells,
modulate oxygen tension, and deliver growth factors involved in
the healing process. Here, we focus only on the process of indi-
rect bone healing, where bone is formed following a cartilage
intermediate in a process called endochondral ossification. The
evidence presented from this compilation of data illustrates an
explicit need to update the existing model of endochondral bone
repair, and emphasizes the potential opportunity for novel thera-
peutic treatments for bone repair that focus on the chondrogenic
and angiogenic stages of repair.
HEMATOMA AND IMMUNE RESPONSE STIMULATE REPAIR
The essential role of the vasculature in bone healing becomes evi-
dent at the onset of the injury as a fracture typically exposes the
bone marrow cavity and disrupts blood vessels within the bone
and surrounding soft tissues. Formation of a hematoma around
the trauma is a critical first step in fracture healing and its absence
will delay healing (8). The hematoma contains the fracture debris
and initiates a pro-inflammatory cascade by recruiting immune
cells from the surrounding soft tissues, lymphatic system, and
vasculature. Within the hematoma a low pH microenvironment
is formed where inflammatory cells secrete pro-inflammatory
cytokines [tumor necrosis factor α (TNFα), interleukin-1β (IL-
1β), and IL-6] to activate the polymorphonuclear neutrophils
and M1 (or pro-inflammatory) macrophages that are recruited
to manage this acute inflammation stage (9). The fibrin network
formed by the hematoma serves as a temporary scaffold for these
leukocytes and this early pro-inflammatory phase has a demon-
strated positive effect on fracture healing (10). Specifically, the
pro-inflammatory phase promotes cell proliferation [IL-1β (11)
and basic fibroblast growth factor, FGF2 (12)], cell differentiation
[matrix metalloproteinase-9, MMP9 (13), and bone morpho-
genetic protein, BMP (14)]. Lactate levels are also high during the
pro-inflammatory stage (15–19), which leads to an upregulation of
angiogenic factors such as angiopoetin-1, platelet derived growth
factor (PDGF), and vascular endothelial growth factor (VEGF)
(20, 21). For additional details see reviews (22–25).
While activation of the fracture repair process seems depen-
dent on an adequate pro-inflammatory response, resolution of
this inflammatory state is critical to progression of healing. The
anti-inflammatory state is the due largely to phenotypic mod-
ulation of the macrophages to the M2 (or alternatively acti-
vated, anti-inflammatory macrophages) population in the fracture
callus. These anti-inflammatory macrophages secrete a battery of
cytokines and growth factors to promote tissue repair and angio-
genesis, such as, IL-10, PDGF,VEGF, transforming growth factor-β
(TGFβ), epidermal growth factor (EGF),and arginase (26). During
fracture a sustained pro-inflammatory state due to dysregulated
macrophage polarization appears to be an underlying mechanism
for delayed healing in conditions such as older age and disease
(27–29) (Figures 1A,B).
DETERMINANTS OF THE FRACTURE HEALING PATHWAY
Following the hematoma and early inflammation stage, fracture
healing can proceed through two different pathways: intramem-
branous or endochondral ossification. Intramembranous ossifica-
tion is the process of direct bone formation, where osteochondral
progenitors differentiate directly into osteoblasts. Osteogenesis
is mediated by the co-expression of the runt-related transcrip-
tion factor 2 (RUNX2) (30–32) and β-catenin (33), which is the
critical transcriptional co-factor for canonical WNT signaling.
Together, activation of these pathways, along with a morpho-
logical shift from the fibroblastic appearance of the progenitor
cell into a more columnar appearance, phenotypically defines the
osteoblast. Osteoblasts synthesize an extracellular matrix contain-
ing Type I collagen and coordinate matrix mineralization in a
highly regulated process that is not fully understood (34–36).
During intramembranous healing, bone spicules created from the
osteoblasts fuse to form a trabeculated bone that is eventually
fully remodeled into a cortical bone ultrastructure through the
coordinated action of osteoblasts and osteoclasts.
Endochondral ossification is the process of indirect bone for-
mation in which bone is formed through a cartilage intermediate.
The cartilage portion of the fracture callus results from chon-
drogenic differentiation of periosteal progenitor cells. Chondro-
genesis is initiated by the expression of SOX9, a member of the
SRY-related high-mobility group box transcription factor fam-
ily required for chondrogenesis (37). SOX9 regulates downstream
synthesis of Type II collagen and aggrecan (38–41), which are the
canonical markers of cartilage. Chondrogenic and osteogenic pro-
grams in the progenitor cell pool oppose each other at a molecular
level. For example, activation of WNT/β-catenin during osteogen-
esis specifically prevents differentiation toward the chondrogenic
lineage by suppressing SOX9 (42, 43).
During fracture healing, both intramembranous and endo-
chondral ossification typically contribute in part to the healing
process, but dominance of healing by one pathway versus the other
is influenced largely by stability at the fracture site. Reduction, or
realignment, of the fracture is a primary goal in successfully treat-
ing the bone to promote healing. Full reduction, which results in
complete stability through the application of fixators such as bone
plates, will promote healing by intramembranous ossification.
More commonly, fractures are reduced to enable some motion,
such as those treated with an intramedullary nail. This promotes a
more robust healing reaction in which endochondral ossification is
the primary healing response within the fracture gap (Figure 1B).
In addition to the mechanical stability of the fracture, the ori-
gin of the progenitor cells that contribute to the fracture callus
also influences the bone healing pathway by providing cells with
distinct differentiation potentials. The osteochondral progenitors
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FIGURE 1 | Endochondral Fracture Schematic: A fracture that is not
rigidly stabilized will heal through a combination of intramembranous
and endochondral ossification. Fracture healing progression: bone is
depicted in red and cartilage in blue, time course corresponds to healing in a
mouse tibia. (A) The first stage of fracture healing is formation of a hematoma
to initiate an inflammatory cascade characterized in part by an abundance of
pro-inflammatory M1 macrophages, low pH, and elevated lactate level.
(B) Next, local osteochondral progenitors differentiate into bone and cartilage
to initiate healing. Intramembranous ossification occurs primarily at the
periosteum and endosteum of the fracture callus, while the soft cartilage
callus forms in the central portion of the fracture where there is maximal
mobility. For healing to progress normally, inflammation must be
down-regulated and there is a shift in the macrophage population from a
pro-inflammatory M1 state to an anti-inflammatory M2 state. (B’) Within the
cartilage callus chondrocytes differentiate and mature in a parallel fashion to
the growth plate. (C) Conversion of cartilage to bone during endochondral
ossification occurs concomitantly with the invasion of blood vessels.
(C’) Blood vessels lead to mineralization of the cartilage matrix and new data
suggest that these cells transform directly into osteoblasts. Chondrocytes do
not undergo significant apoptosis and may re-enter the cell cycle. (D) The
cartilage callus becomes fully converted to a trabeculated bone that will
bridge the full fracture defect. This trabeculated structure will be remodeled
into a cortical bone that is almost indistinguishable in form and function from
the native bone.
that give rise to the fracture callus are recruited locally from the
endosteum and periosteum of the fractured bone (44). The cells
from the endosteum preferentially undergo intramembranous
ossification to directly form osteoblasts and stimulate bridging
bone within the marrow cavity during repair. Conversely, the
periosteal cells appear to be more bi-potent with their fate dictated
by mircoenvironmental forces (45). In fractures that are not rigidly
fixed, these cells will undergo both osteogenesis and chondroge-
nesis in a location specific manner. Along the periosteal surface
of the bone, where there is no motion, cells undergo intramem-
branous ossification; whereas in the fracture gap, the progenitor
cells undergo chondrogenesis to form bone through endochondral
ossification (Figure 1B). While it has been noted that circulating
progenitor cells are recruited to the fracture site during bone
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regeneration, data suggests that their contribution directly to the
fracture callus is minimal (44, 46, 47).
ENDOCHONDRAL FRACTURE REPAIR
The molecular and cellular mechanisms that control endo-
chondral ossification are more complex than intramembranous
ossification. In this pathway, SOX9 expression promotes conden-
sation and commitment of the osteochondral progenitors toward
the chondrogenic lineage. After specification, subsequent SOX9
activity is necessary to maintain cell morphology and the chondro-
genic phenotype through maturation to hypertrophy. In a process
that resembles the well-described process of endochondral ossi-
fication in the growth plate (48), cartilage within the fracture
callus contains a pool of proliferating chondrocytes that succes-
sively undergo hypertrophic maturation prior to attaining a bone
phenotype (Figures 1B,C). While the fracture callus lacks the con-
cise organization of the growth plate, SOX9 expression is easily
detected in the early fracture callus condensation demonstrating
nucleation of chondrogenesis. Subsequently, SOX9 regulates pro-
duction of the cartilage extracellular matrix by directly binding
to the enhancer elements that control collagen II and aggrecan
expression (38–40, 49).
Similar to growth plate chondrogenesis, chondrocytes within
the fracture callus also undergo a controlled and progressive
matruation. Hypertrophic maturation of the chondrocyte is
marked by a strong expression of collagen X in the area where
cartilage transitions to bone. These hypertrophic chondrocytes are
highly bioactive to promote mineralization and vascular invasion
of the cartilage matrix through potent expression of BMP (50),
MMP-13 (51), alkaline phosphatase, VEGF (52–54), and PIGF
(placental growth factor) (55).
The conversion of cartilage to bone in the fracture callus occurs
adjacent to the invading vasculature in a domain that we will
refer to as the “transition zone.” The cartilage in this transi-
tion zone becomes calcified and the extracellular matrix stains as
bone by classic Trichrome or Direct Red histology techniques, yet
the cells retains their hypertrophic morphology (Figures 2A,B).
These hypertrophic chondrocytes also demonstrate significantly
overlapping phenotypes with other distinct bone markers, such
as collagen I, osterix (OSX), osteocalcin (OC), and osteopontin
(OPN) (56–59). The ultimate fate of the hypertrophic chon-
drocytes prior to bone formation has been debated and will be
discussed separately below. However, the general steps that are
agreed upon are: that the calcified cartilage matrix is resorbed,
replaced by bone, and remodeled into functional bone that resem-
bles the original cortical bone through the action of osteoblasts
and osteoclasts/chondroclasts.
ROLE OF OXYGEN IN FRACTURE HEALING
Oxygen tension in the fracture callus changes during the process
of endochondral bone formation (27), having both a direct and
indirect effect on healing. As is the case for any tissue, oxygen deliv-
ery by the vasculature has a direct effect on cell survival. Ischemic
fractures created in a murine model demonstrate increased apop-
tosis of the periosteal progenitor cells to produce delayed fracture
healing in a manner that parallels the clinical condition (1, 2).
FIGURE 2 | Vasculature in the fracture callus transition zone:
(A,B) Histology of fracture callus 10 days following injury stained with
Hall’s and Brudt’s Quadruple (HBQ) stain that indicates the cartilage
matrix in blue through alcian blue and the bone matrix in red through
direct red dye. We have defined the region where the cartilage becomes
bone in the fracture callus as the transition zone (“TZ”). In this region, the
cartilage (“C”) matures through hypertrophy (“HC”) and junctions into
bone in an area that is clearly marked by the blue to red matrix transition
and the invasion of blood vessels (“BV”). Within the red bone matrix (“B”)
cells with the large round hypertrophic chondrocyte morphology and the
smaller elongated osteoblast morphology can be clearly identified.
(C–F) Immunohistochemistry to VEGF protein. (C,D) The transition from
normal to hypertrophic cartilage demonstrates that only hypertrophic
chondrocytes make VEGF. (E,F) At the hypertrophic cartilage to bone
transition this VEGF is responsible for recruiting the vasculature.
Osteocytes no longer make VEGF protein but the protein binds to the
extracellular matrix in this transition zone. (G,H) Immunohistochemistry to
PECAM/CD31 protein marks the vasculature invading in the transition zone.
Scale bar=100µm; B=bone, BV=blood vessel, C= cartilage,
HC=hypertrophic cartilage, TZ= transition zone.
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Decreased oxygen at the fracture (27) may contribute to the pro-
duction of angiogenic factors (20) and vasodilation (9) of the
soft tissues surrounding the fracture. Stabilization of hypoxia-
inducible factor 1α (HI-1α), directly regulates Sox9 expression
in the condensed mesenchymal cells to promote chondrogenesis,
enable chondrocyte survival, and enhances extracellular matrix
synthesis (60–62). Interestingly, systemic changes in oxygen ten-
sion do not significantly alter chondrogenesis during the early
stages of fracture healing, but hyperoxia increases tissue vascular-
ization and rescues delayed healing in ischemic fractures (21).
Further, increasing angiogenesis by removing anti-angiogenic
signals from thrombospondin-2 stimulates healing of ischemic
fractures (63).
ANGIOGNESIS IN THE FRACTURE CALLUS
During endochondral repair, the fracture callus remains avascu-
lar during the initial soft callus phase. However, as chondrocytes
within the callus mature to hypertrophy, they become potent stim-
ulators of angiogenesis and vascular invasion by secreting VEGF
(52–54), PIGF (55), and PDGF (64) (Figures 2C–H). The impor-
tance of angiogenesis to the progression of fracture healing has
been experimentally demonstrated by inhibiting VEGF through
delivery of a soluble neutralizing VEGF receptor (Flt-IgG) to pro-
duce delayed conversion of the cartilage callus to bone following
impaired vascular invasion (53, 65). These results are supported
by similar studies where animals receiving the anti-angiogenic
immunosuppressant Rapamycin demonstrated significant delays
in endochondral repair (66).
Further evidence for the importance of angiogenesis in fracture
repair is found in the clinical studies demonstrating delayed frac-
ture healing as a result of smoking. Compared with an estimated
9% rate of open-tibia non-union in the non-smoking population,
the LEAP study found smokers presented with a 24% chance of
non-union and that the fractures are more recalcitrant to further
intervention to stimulate healing. A study by Ueng et al. suggests
that one underlying mechanism for this delay is the diminished
vascularization induced by smoking (67). While many studies have
hypothesized that smoking disrupts angiogenesis directly, it has
not been proven.
In addition to delivering oxygen and enabling gas exchange,
new blood vessels also deliver general nutrients necessary for cell
survival and provide an egress for waste products. Blood ves-
sels supply a number of circulating factors that are important
to normal fracture healing, such as, parathyroid hormone (PTH),
insulin, and Vitamin D. Importantly, vascular invasion also corre-
sponds with calcification of the cartilage matrix and transition to
bone. The precise molecular mechanisms, and location of signal-
ing, which facilitate mineralization of the cartilage at the fracture
callus is not clear. Changes in calcium concentration are sufficient
to induce mineralization of these hypertropic chondrocytes, yet
it remains unclear what the source of calcium is and which cells
sense these changes. Mineralization of the cartilage matrix is also
initiated by osteoinductive signals, such as BMP, secreted by both
the chondrocytes themselves (50), and by the vascular endothelial
cells (68, 69).
Conversion of calcified cartilage to bone requires that the car-
tilage matrix is degraded and replaced by bone matrix. Major
differences in the extracellular matrix composition include a con-
version of collagen II in cartilage, to collagen I in bone, and
degradation of the glycosaminoglycans (GAGs) in cartilage. It
remains debated how the extracellular matrix is remodeled dur-
ing this conversion. Hypertrophic chondrocytes make MMP-13,
which is one of the major enzymes responsible for degrading both
collagen II and aggrecan, the major GAG in cartilage. Furthermore,
the vascular endothelial cells secrete MMP-9, one of the gelatinases
with a high specificity for degraded collagens, thereby accelerating
cartilage degradation upon vascular invasion. Alternatively, a cel-
lular degradation of the cartilage matrix may be occurring through
the action of osteoclasts that are delivered to the cartilage matrix
through the vasculature. Osteoclasts are recruited to calcified car-
tilage both by production of the receptor activator of NF-κB ligand
(RANKL) (70, 71) in the hypertrophic cartilage, and by MMP-9
expression in the vasculature (13). Some argue the cellular contri-
bution of the osteoclasts is not required for fracture remodeling
(72), while others claim there is a specialized osteoclasts, called the
“chondroclast” (73, 74), which is unique to cartilage degradation
versus bone. In addition to converting the cartilage matrix to bone
matrix, this remodeling phase also requires a large portion of the
solid matrix be removed to create marrow space within the highly
trabeculated bone structure that is initially formed during boney
remodeling (Figure 2A).
ULTIMATE FATE OF FRACTURE CALLUS (HYPERTROPHIC)
CHONDROCYTES
The commitment and progression of the chondrocyte during
endochondral ossification is a long-standing question that is
not fully understood. In the proliferating and pre-hypertrophic
chondrocytes, SOX9 [and associated co-factors SOX5/6 (38)]
establishes chondrocyte identity and actively represses RUNX2
expression. In this state, hypertrophic maturation is actively inhib-
ited through a complex negative feedback regulatory mechanism
in which Indian Hedghog (IHH) activates PTHrP (parathyroid
hormone related protein) through the molecular mediators Gli
and Patched [see reviews (48, 75–77)]. Hypertrophy proceeds
when loss of PTHrP relieves repression of chondrocyte matura-
tion. Morphologically, the hypertrophic chondrocyte is identified
by a dramatic increase in cell size. A recent study quantified this
growth as a ~20-fold increase in both volume and dry mass (78).
The molecular mechanisms that regulate this enlargement are
unclear, but are likely modulated by sodium ion channels (79)
and can be induced by thyroxine (80), BMPs (81, 82), and insulin-
like growth factor (IGF) (83). The phenotype of the hypertrophic
chondrocyte is also unique relative to earlier maturation states;
a loss of SOX9 is accompanied by expression of collagen X (84),
the canonical marker of the hypertrophic chondrocyte, along with
upregulation of markers traditionally related to a bone pheno-
type such as RUNX2, alkaline phosphatase, collagen I, osterix,
osteocalcin, and osteopontin (56–59).
TERMINAL FATE OF THE HYPERTROPHIC CHONDROCYTE
Traditionally, it was believed that the hypertrophic chondrocytes
exits the cell cycle (85) and represent the terminal differentiation
state. This long held view is standard in the literature referring
to both growth plate biology (48, 86) and fracture repair (25, 87).
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According to this model, hypertrophic chondrocytes undergo pro-
gramed cell death (86, 88–90), then osteoblasts or osteochondral
progenitor cells are delivered via the vasculature to form the bone
matrix that replaces the cartilage (91). Thus a direct role for
the vasculature in endochondral bone formation was thought to
involve delivery of precursor cells (Figure 4).
TRANSFORMATION OF HYPERTROPHIC CHONDROCYTES TO
OSTEOBLASTS AND OSTEOCYTES
In contrast to the model described above, an alternative mech-
anism for bone formation directly from the chondrocyte has
been reported. Recently, we published a paper demonstrating
that cartilage can transform into bone during endochondral bone
repair using a number of different lineage tracing strategies (68).
This work has now been followed by two complementary studies
that demonstrate hypertrophic chondrocytes become osteoblasts
and osteocytes during endochondral bone formation by follow-
ing the fate of cells that expressed the collagen X or aggrecan
gene during murine long bone development and fracture heal-
ing (92, 93). These recent murine studies give credence to earlier
studies from zebrafish (94), avian (95–97), and rabbit (98) mod-
els, which reported chondrocytes were capable of forming bone
directly. Together with other studies that have focused on cell
death in the hypertrophic chondrocytes (99–102), these data sug-
gest that the hypertrophic chondrocyte may not necessarily be
destined for apoptosis. By focusing on the transition zone in
murine fractures, we have found very little evidence of cell apop-
tosis using TUNEL staining (68) (Figure 3). While these data
do not exclude the possibility that a subset of the hypertrophic
chondrocytes undergo apoptosis, a process that is necessary to
create physical space for the bone marrow cavity, it does indicate
that this is not the absolute fate of the hypertrophic chondrocyte
(Figure 4).
The mechanism by which chondrocytes transform into
osteoblasts remains unclear. One possible mechanism is that chon-
drocytes mature directly into osteoblasts, and that the expression
of canonical bone markers in the hypertrophic chondrocyte repre-
sents the natural phenotypic progression of endochondral chon-
drocytes (95, 98, 103–108). The phenotypic plasticity of these
endochondral chondrocytes was highlighted in a study showing
that loss of SOX9 expression in pre-hypertrophic chondrocytes
results in the conversion to osteoblast identity (89).
Another possibility is that the chondrocyte can “de-
differentiate” into a progenitor-like state before becoming bone
(68, 109, 110). Supporting this mechanism, we recently showed
that hypertrophic chondrocytes at the transition zone of the frac-
ture callus express the progenitor marker Oct4A (68). These pos-
sibilities are not mutually exclusive; epigenetic remodeling in the
hypertrophic chondrocyte by histone deacetylases activated by the
pluripotent stem cell programs may enable chromatin remodel-
ing to expose alternatively suppressed bone genes. Furthermore,
it has been suggested that the endochondrally derived osteoblast
may arise from an asymmetric cell division of the hypertrophic
chondrocyte (101, 102). Hypertrophic chondrocytes are tradition-
ally considered to be a post-mitotic cell type: activation of the
progenitor cell genes may be a critical step in allowing these cells
to re-enter the cell cycle.
FIGURE 3 | Cell death is not pervasive at the transition zone: the
established model of endochondral ossification includes cell death of
the hypertrophic chondrocytes. Here, we show TUNEL staining in the
transition zone of the fracture callus to demonstrate that there is minimal
cell death seen in these hypertrophic chondrocytes. (A) Bone marrow, as a
positive control; (B) non-hypertrophic cartilage at tip of fractured bone;
(C,D) transition zone with red dotted line indicating the demarcation
between cartilage (“C”) and bone (“B”) that can be easily distinguished by
cell morphology and bright field microscopy. Scale bar= 100µm.
The transition zone is always immediately adjacent to the
invading vasculature (Figures 1 and 2). Given that the vascu-
lature expresses osteogenic molecules (69), one exciting role for
the vasculature may be in stimulating the progression of the
hypertrophic chondrocyte to become an osteocyte. While, further
work is required to demonstrate this conclusively, our previously
published data show that conditioned media from endothelial
cells causes the cartilage matrix derived from a fracture callus to
mineralize, the first step in the conversion of cartilage to bone (68).
CONCLUDING REMARKS: A NEWMODEL FOR
ENDOCHONDRAL REPAIR
Improving our knowledge of the basic mechanisms underlying
normal and delayed fracture repair are central to developing
improved therapies for bone healing. The information presented
here suggests that the traditional view of endochondral bone repair
needs to be updated in light of new data (Figure 4). Specifically,
these data suggest that the vasculature has a critical role in all
phases of fracture healing and that there are multiple potential tar-
gets for therapeutic intervention. Understanding how the immune
response regulates fracture repair is perhaps the first opportu-
nity to positively influence healing outcomes. The hematoma
formed initiates the inflammatory and angiogenic responses that
are required for appropriate healing.
During endochondral bone repair, formation of a soft cartilagi-
nous callus is the next milestone in fracture healing. The cartilage
itself is a highly angiogenic tissue that may be the primary mech-
anism for recruiting and establishing a functional vasculature and
marrow space in the new bone. In turn, the invading vasculature
is central in coordinating the conversion of the cartilage matrix
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FIGURE 4 | A new model for endochondral fracture repair: local
osteochondral progenitors from the periosteum and endosteum are
the stem cells that differentiate to form bone and cartilage in the
fracture site. To generate the cartilage callus, osteochondral progenitors
differentiate into chondrocytes (blue) that proliferate to generate the early
soft callus. Chondrocytes within the callus mature into hypertrophic
chondrocytes. Expression of angiogenic factors by these cells results in
vascular invasion into the previously avascular soft callus. Mineralization of
the hypertrophic cartilage occurs at this transition zone where blood
vessels are invading. Hypertrophic chondrocytes begin to express many
of the canonical markers of the osteoblast (red), including osteocalcin,
osteopontin, and alkaline phosphatase. The fate of these mineralized
hypertrophic chondrocytes remains unclear. Apoptosis is the classical fate
ascribed to these cells. According to this model, new bone is formed by
osteoblasts that arise from osteoprogenitor cells brought in through the
invading vasculature. In addition, new reports indicate that at least a part
of the newly formed bone in the fracture callus is chondrocyte derived.
The mechanisms that enable this phenotypic conversion of cartilage to
bone remain unclear. Here, we depict two proposed pathways –
chondrocyte de-differentiation and direct maturation – that have been
suggested in the literature, but without fully substantiated details as
suggested by dotted lines.
to bone, both by providing osteoinductive signals (e.g., BMP, oth-
ers), and by bringing osteoclasts in to facilitate remodeling of the
tissue. Classically, it is also believed that the vasculature was the
source of the osteoblasts that form the new bone. Newer data sug-
gest that chondrocytes themselves directly contribute to the new
bone. While this finding does not exclude the possibility that cells
from the invading vasculature do not contribute to endochondral
bone formation (91), it does suggest that invading cells may not
be the only, or even primary, source of cells that form bone during
endochondral repair (68, 92, 93, 98, 107).
After the cartilage is converted to bone the tissue is highly tra-
beculated. Remodeling is the final phase of healing: it allows for
complete bridging of the fracture site, structural integrity, and the
maintenance of the marrow cavity for hematopoiesis. This process
ultimately produces a cortical bone structure that is nearly iden-
tical to the original bone in both form and function through a
tightly regulated coupling of osteoblast and osteoclast activity.
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